Updated Analyses: Safety and Efficacy of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory CD33+ Acute Myeloid Leukemia: A Phase Ib/II Study

Background: Results of therapy for relapsed/refractory (R/R) AML patients (pts) remain poor, with few surviving >2 years. Refractoriness to treatment may be due to the resistance of quiescent leukemia stem cells (LSCs) to conventional chemotherapy. Gemtuzumab Ozogamicin (GO), a monoclonal antibody linked to the cytotoxin calicheamicin, targets CD33, an antigen with variable expression on LSC. However, decreased blast CD33 expression, p-glycoprotein upregulation and decreased mitochondrial apoptosis are recognized mechanism of resistance to GO (Linenberger et al Leukemia 2005; 19:176-82). GO-induced apoptosis requires Bax and Bak effectors and is opposed by the anti-apoptotic proteins BCL-2 and BCL-XL. Thus, Venetoclax (VEN), a BH3 mimetic with high affinity for BCL-2 should facilitate GO-mediated LSC apoptosis. In addition, LSC, due to their reliance on oxidative phosphorylation (Lagadinou, Cell Stem Cell 2013, 12:329-41) are also uniquely sensitive to BCL-2 inhibition. Thus, we hypothesized a potential synergy between these drugs in targeting LSC in R/R AML.

Study design: Big Ten Cancer Research Consortium (BTCRC)-AML17-113 is a single arm, open-label, multi-center, dose-escalation phase Ib/II study of the combination of GO and escalating doses of VEN in R/R AML pts (18-75y), using a 3+3 design. Correlative studies include pre-treatment AML blast CD33 expression and BH3 profiling, minimal residual disease (MRD) measurements at post-therapy time points using digital drop PCR technology, and quality of life (QOL) assessments (EORTC QLQ-C30, FACT-Fatigue).

Methods: The primary endpoint is to determine the maximum tolerated dose (MTD) of VEN with GO. Secondary endpoints include overall response rate (ORR), anti-leukemic activity, characterization of treatment emergent adverse events (TEAEs), and estimates of relapse free survival (RFS), event free survival (EFS), and overall survival (OS).

Eligibility: ECOG 0-2, adequate organ function, CD33+ in ≥20% AML blasts, ≤2 lines of prior therapy, no prior use of GO, no history of veno-occlusive disease (VOD), no BMT within 2 months, no CNS disease or HIV.

Induction: 3-day VEN ramp-up to the target dose of 200 (cohort #1), 400 (#2), or 600 (#3) mg daily x 28d, with GO 3mg/m² infused d1, 4, and 7.

Consolidation/Maintenance: If CR/CRi achieved, pts proceed to BMT if applicable. If no BMT, or if partial response (PR), pts are consolidated with VEN at the prescribed dose x 28d with GO 3mg/m² given d1 and 4 (Cycle 2). If BMT not applicable, and in CR/CRi, VEN alone is then given as maintenance in cycles 3+ until disease progression or toxicity.

Updated Analysis: Trial design was previously described by Arain, S et al. JCO 2020, 15:suppl. TPS7566. Cohort#3 is completing accrual with the last of 6 patients currently undergoing induction treatment. Enrollment n=12 pts. Barriers to accrual have been the COVID-19 pandemic and widespread use of VEN/HMA by referring community oncologists. The study has been amended to allow for prior use of VEN containing regimens.

SAE: Respiratory failure gr 3 (n=1), febrile neutropenia (FN) gr 3/4 (n=3), Anemia/rectal pain gr 3/4 (n=1).

TEAE:(%;max grade (gr)): thrombocytopenia and anemia (both 60%;gr 4); neutropenia (40%;gr 4); pruritus (30%;gr 3); FN (20%;gr 4), weight loss, diarrhea , headache, constipation (all 20%;gr 1-2).

Outcomes: None of the 6 pts in cohorts #1 and #2 responded to treatment. One pt developed VOD gr 4, related to the use of total marrow irradiation conditioning regimen post-induction with GO/VEN. In cohort #3, 3 patients are in CR (one post-HSCT), 2 are undergoing induction and 1 has progressed.

Conclusion: The updated analysis of this study reveals a well tolerated drug combination with low toxicities, demonstrating responses in cohort#3 (VEN 600 mg). We plan to expand accrual to this cohort adding 6-12 pts. This trial is registered at clinicaltrials.gov as NCT040768.

Arain:Astellas Pharma: Current Employment. Patel:Exelixis: Current Employment. Saraf:Agios: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; ORIC: Consultancy; Global Blood Therapeutics: Consultancy, Research Funding, Speakers Bureau; FORMA Therapeutics: Consultancy, Research Funding. Calip:Roche: Current equity holder in publicly-traded company; Pfizer: Research Funding; Flatiron Health, Inc.: Current Employment. Quigley:Alnylam: Speakers Bureau; Agios: Speakers Bureau; Rigel: Other: Advisory Board; Servier: Speakers Bureau.